Search

Your search keyword '"Ahlenstiel G"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Ahlenstiel G" Remove constraint Author: "Ahlenstiel G" Database OAIster Remove constraint Database: OAIster
33 results on '"Ahlenstiel G"'

Search Results

1. Global multi-stakeholder endorsement of the MAFLD definition

2. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

3. The psychometric properties of the grazing questionnaire in an obesity sample with and without binge eating disorder.

4. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics.

5. Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis.

6. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics.

7. Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis.

8. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics

9. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study.

10. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study.

11. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

12. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

13. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

14. Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience.

15. Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis

16. Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience.

17. CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury.

18. CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury.

19. FibroGENE: A gene-based model for staging liver fibrosis

20. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

21. FibroGENE: A gene-based model for staging liver fibrosis

22. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

23. A Summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses

24. CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection

25. CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection

26. Association of IFNL3 polymorphisms with fibrosis progression in viral and non-viral chronic liver disease

27. Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection

28. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic Hepatitis C virus infection in a European cohort: A cross-sectional study

29. IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study

30. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort

31. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic Hepatitis C virus infection in a European cohort: A cross-sectional study

32. Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level

33. Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level

Catalog

Books, media, physical & digital resources